Document Classification

Section Type: RESULTS

Text: The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0. 8 points for the ADAS-cog11 score (95 % confidence interval [CI], -2. 1 to 0. 5 ; P = 0. 24) and -0. 4 points for the ADCS-ADL score (95 % CI, -2. 3 to 1. 4 ; P = 0. 64) in EXPEDITION 1 and -1. 3 points (95 % CI, -2. 5 to 0. 3 ; P = 0. 06) and 1. 6 points (95 % CI, -0. 2 to 3. 3 ; P = 0. 08), respectively, in EXPEDITION 2.